CMS87542

Dear Discovery Team,

I trust you are well.

Following my conversation with your team 05/05/2026, I was advised that both Macrodentin and Urton are covered as PMB medications until April 2027, and that no co-payment should be required.

However, this information appears to contradict the recent charge app**** under CMS reference number 87542, as well as the contents of the attached letter from the Medical Ombudsman,Urodynamic report and Dr Urry, which suggests otherwise. Additionally, over the past few months, I have not been required to make any co-payments for either medication, further highlighting this inconsistency.

This is despite my neuropathic bladder condition, for which I have been receiving these medications without any co-payment. The sudden introduction of a co-payment, together with an increase in my monthly medical premium, appears to be inconsistent and has been app**** inappropriately. It is also important to note that both medications being supp**** are already generic options, which further raises concern regarding the application of a co-payment.

Furthermore, on the occasions where I did make payments, I was subsequently requested to submit all receipts for reimbur*****t. This introduces yet another contradictory requirement, leaving the patient out of pocket and adding to the overall confusion regarding my benefits and coverage.

This matter is of urgent concern, as I am currently without my prescribed medication, despite Dr Urry having provided a renewed script.

I kindly request your urgent clarification regarding:

My current PMB coverage status for Macrodentin and Urton The reason for the co-payment of R196.02 under reference 87542 The basis for the recent increase in my monthly medical premium The reason for being asked to pay upfront and then submit receipts for reimbur*****t Confirmation that the necessary updates will be made to prevent further delays at the pharmacy Your prompt assistance in resolving this issue would be greatly appreciated, as it is directly impacting my ability to access essential medication.

Thank you for your attention to this matter.

Kind regards, M. Hassen